The first drug developed to specifically target a mutation involved in the pathogenesis of lymphoma, represents a ‘paradigm shift’ in the management of relapsed or refractory B-cell non-Hodgkin lymphomas. Speaking after the CLL ARC Forum in Sydney recently, Professor John Seymour told the limbic tazemetostat was ‘not going to be a household name’ but was important for ...
Novel therapies highlighted at CLL ARC Forum
By Mardi Chapman
27 Jul 2017